Tasly Pharmaceutical Group Co., Ltd (SHA:600535)

China flag China · Delayed Price · Currency is CNY
16.30
-0.11 (-0.67%)
Jun 6, 2025, 3:00 PM CST
17.77%
Market Cap 24.35B
Revenue (ttm) 8.50B
Net Income (ttm) 974.68M
Shares Out 1.49B
EPS (ttm) 0.65
PE Ratio 24.98
Forward PE 18.42
Dividend 0.53 (3.23%)
Ex-Dividend Date Mar 26, 2025
Volume 8,891,098
Average Volume 14,821,261
Open 16.42
Previous Close 16.41
Day's Range 16.26 - 16.50
52-Week Range 12.24 - 17.77
Beta 0.44
RSI 59.10
Earnings Date Aug 22, 2025

About SHA:600535

Tasly Pharmaceutical Group Co., Ltd engages in the pharmaceutical business in China and internationally. The company provides prescription drugs covering various therapeutic areas, including cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, soothe the nerves, pruritus, and andrological areas, as well as over-the-counter drugs. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is headquartered in Tianjin, China. [Read more]

Sector Healthcare
Founded 1994
Employees 10,958
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600535
Full Company Profile

Financial Performance

In 2024, SHA:600535's revenue was 8.50 billion, a decrease of -2.03% compared to the previous year's 8.67 billion. Earnings were 955.59 million, a decrease of -10.78%.

Financial Statements

News

There is no news available yet.